MiniMed to show MiniMed Flex™ and MiniMed Go™, supported by new clinical and real-world evidence across its connected diabetes technology portfolio

NORTHRIDGE, Calif., September 25, 2026 – MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan from September 28-October 2.

At EASD, MiniMed will showcase technologies designed to ease the daily burden of diabetes while delivering strong clinical outcomes. Through advanced automation and smaller, more intuitive designs, the company remains focused on a simple goal: making every day better for people with diabetes.

European physicians will have their first opportunity to experience the MiniMed Flex™ system, a next generation, screenless pump controlled through an app and featuring real-time SmartGuard™ automation, following its CE (Conformité Européenne) Mark announcement earlier this month and ahead of its planned European launch in November. Attendees can also explore MiniMed Go™, a smart insulin pen system that remembers, reminds, and recommends the right dose for people who manage their diabetes with multiple daily injections.

MiniMed’s Exhibit (Booth X.02) will feature hands-on demonstrations of our diabetes technology and support offerings for healthcare professionals and people with diabetes.

MiniMed will also present clinical and real-world data showing the impact of its connected solutions, including its recently refreshed sensor portfolio.

MiniMed Sponsored Events

The following symposia will feature discussions with MiniMed and independent speakers. Details are as follows:

• Arena Talk session titled "Reshaping MDI Therapy with MiniMed Go™" will showcase the MiniMed Go™ system and share clinical insights on Thursday, October 1, 17:00-17:30 p.m. CET in the Arena. It will be co-chaired by Goran Petrovski, MD, MSc, PhD, Medical Affairs Director, Minimed and Dario Pitocco, Associate Professor of Endocrinology at Università Cattolica del Sacro Cuore, Rome. Director of Diabetology Unit at Policlinico Universitario Agostino Gemelli, Rome. The session will feature contributions from Dr. Martin Cuesta, MD, PhD Hospital Clinico San Carlos, Spain and Prof. Lutz Heinemann MD, Science Consulting in Diabetes, Düsseldorf, Germany and San Diego, USA.

• Hot Topic session titled "Facts vs Myths in AID treatment" will challenge some of the most common misconceptions about automated insulin delivery therapy on Friday, October 2 at 11:00-11:30 a.m. CT, at the Spotlight Stage. It will be co-chaired by Ohad Cohen, MD, Sr. Medical Affairs Director, Minimed and Ilaria Dicembrini, Associate Professor of Endocrinology, University of Florence. Deputy Director, Diabetes and Metabolic Diseases Unit, Ospedale Universitario di Careggi, Firenze, Italy. The session will feature insights from Prof. Amir Tirosh, Director of Division of Endocrinology, Diabetes and Metabolism at Sheba Medical Center and Tel-Aviv University, Israel and Martijn Vrouenraets, Diabetes Clinic Medical Spectrum Twente, the Netherlands.

Scientific Presentations

The following poster and oral scientific data presentations represent the work of MiniMed employees and independent investigators using MiniMed devices in their research.

• “Performance of the Newly Introduced Instinct Sensor with the MiniMed™ 780G System: A Real-World Study of 4,364 Users in the United States” – Oral presentation by John J. Shin, PhD, MBA, Sr. Clinical Research Director, MiniMed on Thursday, October 1 at 10:45 CET in the Milan Hall.
• “The Smart MDI System in People with Type 1 Diabetes and High HbA1c: A Randomized Controlled Trial Demonstrating that Response to Notifications Drives Outcomes” – Oral presentation by Prof. Laurent Crenier, MD, PhD, Head of Endocrinology Department, University Hospital Brussels, Belgium on Friday, October 2 at 10:00 CET in the Milan Hall
• “Efficacy and Safety of the MiniMed™ Fully Closed-Loop (FCL) system - Glycemic outcomes in a 9-Week, Unsupervised Home Study” – Oral Presentation by Ohad Cohen, MD, Sr. Medical Affairs Director, Minimed on Friday October 2, 10:00 in the Milan Hall. 
• “Sensor continuity and glycaemic outcomes during the first four months of MiniMed™ 780G use with Instinct CGM: real-world data from 11,520 users – Short Oral Presentation by Jennifer McVean, MD, Sr. Medical Director, MiniMed on Thursday, October 1 at 14:00 at Station 24.
• “Switching from predictive low glucose suspend to advanced hybrid closed-loop pump therapy improves metabolic control and quality of life in children with type 1 diabetes“– Short oral presentation by Sorin Dorian Ioacara, Associate Professor, Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania on Tuesday September 29 at 13:15 at Station 15.
• “Glycemic Concordance of Simplera Sync™ and Instinct Sensors in MiniMed™ 780G System Users: A Randomized Crossover Study” – Short oral presentation by Maya Laron Hirsh B.Sc., Sheba Medical Center, Israel on Wednesday, September 30 at 11:45 at Station 16

About MiniMed

MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:

Andrew Crawford

Public Relations

+41 79 378 1932

Ryan Weispfenning

Investor Relations

+1-763-505-4626